A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

NCT01493505 Phase 3 TERMINATED

The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.

Details

Lead sponsor	Amgen
Phase	Phase 3
Status	TERMINATED
Enrolment	1015
Start date	2012-01
Completion	2016-12

Conditions

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Interventions

• AMG 386
• Paclitaxel
• AMG 386 Placebo
• Carboplatin

Primary outcomes

• Progression free survival — 3 years

Countries

United States, Austria, Belgium, Canada, Denmark, Germany, Greece, Hong Kong, Italy, Japan, Netherlands, Russia, South Korea, Spain